# EDGAR Filing Document

**Accession Number:** 0001892500
**File Stem:** 0001213900-26-068251
**Filing Date:** 2026-6
**Character Count:** 9440
**Document Hash:** d88fde6345fbac463d332cd5ccdb586a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-068251.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001213900-26-068251

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260612

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clearmind Medicine Inc.
- **CENTRAL INDEX KEY:** 0001892500
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41557
- **FILM NUMBER:** 261086420

**BUSINESS ADDRESS:**
- **STREET 1:** 101-1220 WEST 6TH AVENUE
- **CITY:** VANCOUVER, BRITISH COLUMBIA
- **STATE:** Z4
- **ZIP:** V6H1A5
- **BUSINESS PHONE:** 972-54-5704749

**MAIL ADDRESS:**
- **STREET 1:** 101-1220 WEST 6TH AVENUE
- **CITY:** VANCOUVER, BRITISH COLUMBIA
- **STATE:** Z4
- **ZIP:** V6H1A5

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: June 2026

Commission file number: 001-41557

**<u>CLEARMIND MEDICINE INC.</u>**

(Translation of registrant's name into English)

**101 – 1220 West 6th Avenue**

**Vancouver, British Columbia**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**<u>CONTENTS</u>**

As previously announced, on April 30, 2026, Clearmind Medicine Inc. (the "Company") entered into an amendment to the securities purchase agreements dated September 17, 2025 (as amended, the "SPAs") with investors (the "CLA Investors") pursuant to which the Company shall issue and sell, from time to time, convertible promissory notes (the "Promissory Notes") in the aggregate principal amount of up to $10,000,000.

The Company is announcing that on June 12, 2026, it entered into an agreement with the CLA Investors pursuant to which the Company shall issue and sell Promissory Notes to the CLA Investors in the aggregate principal amount of $1,000,000 for an aggregate purchase price payable in cash equal to 90% of the principal amount, or $900,000. In connection with this agreement, the parties also agreed to amend the floor price applicable to the conversion price formula set forth in the Promissory Notes to $1.875 per common share. The transaction is expected to close on or about June 14, 2026.

The foregoing description of the agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, which is attached as an exhibit to this Form 6-K and incorporated herein by reference.

This Form 6-K incorporated by reference into the Registrant's Registration Statements on Form F-3 (File Nos. [333-275991](http://www.sec.gov/Archives/edgar/data/1892500/000121390023094809/ea189816-f3_clearmind.htm), [333-270859](http://www.sec.gov/Archives/edgar/data/1892500/000121390024004506/ea191622-posam_clearmind.htm), [333-273293](http://www.sec.gov/Archives/edgar/data/1892500/000121390024004506/ea191622-posam_clearmind.htm), [333-293521](https://www.sec.gov/Archives/edgar/data/1892500/000121390026017379/ea0277219-f3_clear.htm) and [333-295455](https://www.sec.gov/Archives/edgar/data/1892500/000121390026050265/ea0288494-f3_clearmind.htm)) and Form S-8 (File No. [333-283695](http://www.sec.gov/Archives/edgar/data/1892500/000121390024107014/ea0224059-s8_clearmind.htm)), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**<u>EXHIBIT INDEX</u>**

---

| | |
|:---|:---|
| **Exhibit No.** |  |
| 99.1 | [Agreement dated June 12, 2026 regarding Additional Purchase of Convertible Promissory Notes.](ea029459201ex99-1.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Clearmind Medicine, Inc.** | **Clearmind Medicine, Inc.** |
|  | (Registrant) | (Registrant) |
| Date: June 12, 2026 | By: | /s/ *Adi Zuloff-Shani* |
|  | Name: | Adi Zuloff-Shani |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**<u>AGREEMENT</u>**

This Agreement (this "Agreement") is entered into as of June 12, 2026 (the "Effective Date"), by and between Clearmind Medicine Inc., a British Columbia corporation (the "Company"), and the accredited investors party hereto (each, a "Buyer").

**WHEREAS**, on April 30, 2026, the Company entered into that certain Amendment to Securities Purchase Agreement with the Buyers (as amended, the "SPA"), pursuant to which the Company shall issue and sell, from time to time, convertible promissory notes (each, an "Additional Note"), in the aggregate principal amount of up to $10,000,000 to the Buyers;

**WHEREAS**, Section 1(c) of the SPA provides that the Company may request, at its sole discretion, that the Buyers will purchase Additional Notes in the aggregate principal amount of $2,500,000 per fiscal quarter (the "Quarterly Limit");

**WHEREAS**, the Company and the Buyers wish to exceed the Quarterly Limit on a one time basis, such that Buyers shall purchase Additional Notes in the aggregate principal amount of $1,000,000 on the date hereof; and

**WHEREAS**, the Company and the Buyers wish to amend the Conversion Price formula set forth in the Additional Notes and agree on an amended floor price.

**NOW, THEREFORE**, in consideration of the mutual covenants and agreements herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Buyers agree as follows

1. <u>Definitions</u>. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the SPA.

2. <u>Additional Purchase</u>. Notwithstanding anything to the contrary in the SPA, on the date hereof the Company shall issue and sell to the Buyers, and the Buyers shall purchase from the Company, Additional Notes in an aggregate principal amount of $1,000,000 (the "Additional Purchase"), for an aggregate purchase price payable in cash equal to 90% of the principal amount, or $900,000.

3. <u>Allocation; Pro Rata Portions</u>. Each Buyer's pro rata portion of (i) the aggregate principal amount of the Additional Notes and (ii) the aggregate purchase price for the Additional Purchase is set forth on Annex A attached hereto.

4. <u>Funding Instructions</u>. Each Buyer shall remit its respective purchase price amount set forth on Annex A, in immediately available funds, by wire transfer to an account to be provided by the Company to each Buyer.

5. <u>Floor Price</u>. The definition of "Floor Price" in the Additional Note attached as Exhibit A to the SPA shall be amended to mean $1.875 per Common Share.

6. <u>No Waiver of SPA Rights</u>. Except as expressly set forth herein: (a) all terms and conditions of the SPA remain in full force and effect; (b) the Additional Purchase remains subject to Section 1(c) of the SPA; and (c) nothing herein shall be deemed to waive, limit, or modify any rights or remedies of any party under the SPA or any Additional Note.

7. <u>Governing Law</u>. This Agreement, and the rights and obligations of the parties hereunder, shall be governed by, and construed in accordance with, Section 8(a) of the SPA, which provision is hereby incorporated by reference mutatis mutandis as if fully set forth herein.

8. <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same agreement.

9. <u>Further Assurances</u>. Each party agrees to execute such further documents and take such further actions as may be reasonably necessary to effectuate the purposes of this Agreement.

**[REMAINDER PAGE INTENTIONALLY LEFT BLANK]**

**IN WITNESS WHEREOF**, the parties have executed this Agreement as of the date first written above.

---

| | |
|:---|:---|
| **CLEARMIND MEDICINE INC.** | **CLEARMIND MEDICINE INC.** |
| **By:** |  |
| **Name:** | **Adi Zuloff-Shani** |
| **Title:** | **Chief Executive Officer** |
| **By:** |  |
| **Name:** | **Hila Kiron-Revach** |
| **Title:** | **Chairman of the Board** |

---

---

| | |
|:---|:---|
| **L.I.A Pure Capital Ltd.** | **L.I.A Pure Capital Ltd.** |
| **By:** |  |
| **Name:** | **Kfir Silberman** |
| **Title:** | **Chief Executive Officer** |

---

---

| | |
|:---|:---|
| **Capitalink Ltd.** | **Capitalink Ltd.** |
| **By:** |  |
| **Name:** | **Lavi Krasney** |
| **Title:** | **Chief Executive Officer** |

---

**<u>ANNEX A</u>**

<br> **Allocation of Additional Notes and Purchase Price**

---

| | | |
|:---|:---|:---|
| **Buyer Name** | **Principal<br> Amount of<br> Additional<br> Note** | **Purchase<br> Price<br> (90%)** |
| L.I.A. Pure Capital Ltd. | $500000 | $450000 |
| Capitalink Ltd. | $500000 | $450000 |
| **Total** | $**1000000** | $**900000** |

---